Search - tctmd.com

Displaying 1 - 20 of 52

Sort: Relevancy | Date

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Conference News TCT 2024

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

Yael L. Maxwell

October 29, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

Aspirin Use Ups Risk of Anemia in Elderly Patients: ASPREE

Michael O'Riordan

June 22, 2023

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News EACTS 2022

FFR/iFR No Help in CABG Surgery in SWEDEHEART Registry

Michael O'Riordan

October 07, 2022

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Daily News

Age and Fitness Biggest Predictors of Mortality in CAD Patients, AI Study Shows

Michael O'Riordan

May 04, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

News Daily News

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Michael O'Riordan

August 26, 2021

Crushing Prasugrel Tabs Ups Platelet Inhibition Following Primary PCI

News Daily News

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Yael L. Maxwell

June 22, 2021

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

Todd Neale

May 18, 2021

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Daily News

‘Gaming’ the AUC for Revascularization? Study Suggests Not

Michael O'Riordan

March 25, 2021

Advertisement

ACC: It’s Time for Clinicians to Address Inflammation in CVD

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Aspirin Use Ups Risk of Anemia in Elderly Patients: ASPREE

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

FFR/iFR No Help in CABG Surgery in SWEDEHEART Registry

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Age and Fitness Biggest Predictors of Mortality in CAD Patients, AI Study Shows

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

‘Gaming’ the AUC for Revascularization? Study Suggests Not

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content